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Gestational	 Diabetes	 Mellitus	 (GDM)	 affects	 between	 3-10%	 of	 pregnancies	 with	
consequences	 for	 both	 the	 mother	 and	 the	 newborn	 infant.	 The	 target	 of	 GDM	




easiest	 route	 of	 administration	 of	 medication	 and	 dosing	 schedule	 to	 increase	 their	
concordance.	 Therefore,	 attention	 has	 turned	 to	 looking	 at	 the	 use	 of	 oral	
hypoglycaemic	agents	(OHAs)	for	the	treatment	of	GDM.	There	are	two	classes	of	OHAs	
used	 in	 pregnancy:	 biguanides	 (for	 example	 metformin)	 and	 sulphonylureas	 (for	
example	glibenclamide,	also	known	as	glyburide).		
In	the	placenta	a	network	of	apical	ATP-binding	cassette	(ABC)	transporters	facilitates	
the	 efflux	 of	 substances	 away	 from	 the	 fetus,	 thereby	 protecting	 the	 fetus	 from	
exposure	 to	 unwanted	 substances	 including	 medications	 such	 as	 metformin	 and	
glibenclamide.	In	this	thesis,	I	have	examined	the	mRNA	levels	of	P-glycoprotein	(P-gp),	
Breast	 cancer	 resistance	 protein	 (BCRP)	 and	Multidrug	 resistance-associated	 protein	
(MRP)	 in	placentas	 from	women	with	GDM.	 I	have	demonstrated	a	 reduction	 in	P-gp	
mRNA	 expression	 among	 placentas	 from	 those	 women	 treated	 with	 metformin	 and	
insulin	 compared	 to	 placentas	 from	 women	 without	 GDM	 and	 those	 treated	 with	









While	 treatment	 with	 OHAs	 is	 becoming	 standard	 care	 in	 the	 management	 of	 GDM,	
little	work	 has	 been	 done	 looking	 at	 those	mechanisms	 in	 place	 to	 protect	 the	 fetus	
from	 such	 treatments.	 Future	developments	 in	 the	management	 of	GDM	are	 likely	 to	
include	 combining	metformin	 and	 glibenclamide;	 the	work	 in	 this	 thesis	 provides	 in	















complications.	 It	 is	 known	 that	 treating	 these	 women	 with	 medications	 during	
pregnancy	 can	 reduce	 these	 risks.	 The	 traditionally	 accepted	 treatment	 was	 with	
insulin	 injections,	 however;	more	 recently	 these	women	 have	 been	 treated	with	 two	
types	of	tablets	with	good	effect.		
Whilst	 there	 have	 been	 several	 studies	 showing	 that	 these	 tablets	 are	 effective	 at	









In	 this	report	we	have	 looked	at	 these	transporter	proteins	 in	placentas	 from	women	
who	 had	 gestational	 diabetes	 during	 their	 pregnancies	 and	 compared	 them	 to	
placentas	from	women	who	did	not	have	diabetes	in	pregnancy.	We	have	shown	that	in	









those	 from	women	with	diabetes	 treated	only	with	 tablets	and	 those	women	without	
diabetes.	
We	went	on	to	analyse	how	exposing	placental	tissue	to	these	medications	would	affect	




is	 unlikely	 to	 put	 the	 unborn	 baby	 at	 unwanted	 risk	 from	 exposure	 to	 high	 levels	 of	
these	 tablets.	 We	 have	 also	 shown	 that	 combining	 the	 two	 tablets	 (an	 aspect	 of	























































































































Gestational	 Diabetes	 Mellitus	 (GDM)	 affects	 between	 3-10%	 of	 pregnancies	 with	
consequences	 for	 both	 the	 mother	 and	 the	 newborn	 infant	 [1].	 The	 target	 of	 GDM	








GDM.	 There	 are	 two	 classes	 of	 OHAs	 used	 in	 pregnancy;	 biguanides	 (for	 example	
metformin)	 and	 sulphonylureas	 (for	 example	 glibenclamide).	 Both	 oral	 agents	 have	
become	recognised	forms	of	treatment	of	GDM.	
In	the	placenta	there	is	a	network	of	apical	ABC	transporters	that	are	in	place	to	protect	
the	 fetus	 from	 exposure	 to	 unwanted	 substances	 including	 medications	 such	 as	
metformin	 and	 glibenclamide.	 In	 this	 thesis,	 I	 have	 examined	 the	mRNA	 and	 protein	
levels	 of	 these	 transporters	 in	 placentas	 from	women	with	GDM,	 and	 the	 effect	 of	 in	
vitro	treatment	with	metformin	and	glibenclamide	on	transporter	expression	to	assess	
the	 impact	 of	 giving	 both	 these	medications	 together	 in	 pregnancies	 complicated	 by	
GDM.	
This	report	will	begin	with	an	introduction	to	GDM	(chapter	1),	followed	by	a	review	of	
the	 literature	 regarding	 the	 network	 of	 placental	 ABC	 transporters	 that	 transport	





















Gestational	 Diabetes	 Mellitus	 (GDM)	 can	 be	 defined	 as	 carbohydrate	 intolerance	 of	
variable	 severity	 with	 onset	 or	 first	 recognition	 during	 pregnancy,	 presenting	 with	















glucose	 and	 protein	 loads.	With	 regard	 to	 glucose	metabolism,	 insulin	 has	 two	main	


























the	 circulation	 and	 into	 cells;	 and	 inhibiting	 gluconeogenesis	 in	 the	 liver	 (glucose	
production)	with	the	overall	effect	of	decreasing	blood	glucose	levels.		
1.1.2	Normal	Pregnancy	
	Pregnancy	 itself	 is	 a	diabetogenic	 state,	 associated	with	 increasing	 insulin	 resistance	
due	 to	 the	 insulin-antagonistic	 actions	 of	 the	 placental	 hormones	 human	 placental	
lactogen	 (HPL),	 progesterone	 and	 prolactin	 [4].	 Throughout	 pregnancy,	 increasing	
levels	 of	 placental	 hormone	 production	 result	 in	 rising	 insulin	 resistance	 with	
gestation.	 In	 both	 non-diabetic	 pregnant	 women	 and	 women	 with	 GDM	 there	 is	 an	
almost	 doubling	 in	 fasting	 plasma	 insulin	 levels	 compared	 to	 the	 non-pregnant	 state	
[5].	 It	has	been	demonstrated	that	 insulin	production	 in	response	to	glucose	stimulus	
increases	 in	pregnancy	 (as	a	 result	of	β-cell	hypertrophy	and	hyperplasia	 [6]),	whilst	
the	 responsiveness	 of	 peripheral	 tissues	 and	 the	 liver	 to	 this	 higher	 insulin	 level	 is	














of	 100g	 glucose	 in	 control	 subjects	 and	 in	 20-	 to	 30-week	 pregnant	 women.	 (Adapted	 from	
Puavil	et	al.)	[9]	
Figure	2	demonstrates	that	whilst	the	insulin	response	to	a	glucose	load	may	be	higher	




















































Figure	 3:	 Longitudinal	 changes	 in	 plasma	 inulin-glucose	 ratio	 during	 OGTT	 (mean)	 in	 pre-
gravid	women,	in	early	pregnancy	(12-14	weeks)	and	late	pregnancy	(34-36	weeks).	[Adapted	
from	Catalano	et	al.]	[10]	
The	 hypothesis	 that	 the	 increased	 insulin	 levels	 seen	 are	 solely	 the	 result	 of	 higher	
background	 serum	 glucose	 levels	 in	 pregnancy	 has	 been	 disproven	 through	
demonstration	 that	 infusing	 glucose	 to	 achieve	 serum	 glucose	 levels	 that	 are	
comparable	in	women	with	GDM	and	normal	glucose	tolerant	(NGT)	pregnant	women	





on	 that	 pathological	 processes	 can	 occur	which	 result	 in	 the	 heterogeneous	 disorder	
which	is	GDM,	either	through	a	failure	to	make	the	necessary	rise	in	insulin	production	
demonstrated	 above,	 through	 a	 reduced	 peripheral	 responsiveness	 to	 endogenous	






























insulin	 levels,	 approximately	 twice	 non	 pregnant	 (postpartum)	 levels	 [12].	 However,	
obese	women	with	GDM	have	significantly	higher	fasting	insulin	levels	when	compared	
to	non-obese	women	with	GDM	and	pregnant	women	with	NGT[13].		
Whilst	women	with	GDM	have	 significantly	higher	 insulin	 response	 to	a	 glucose	 load	
compared	to	postpartum,	this	insulin	peak	has	been	demonstrated	to	occur	later	than	
that	in	pregnant	women	with	NGT	[12].	Hence,	a	glucose	load	results	in	higher	serum	
glucose	 for	 a	 longer	 period	 in	 women	 with	 GDM	 compared	 to	 those	 with	 NGT.	
Furthermore,	whilst	the	absolute	 insulin	response	was	comparable	between	pregnant	
women	 with	 GDM	 and	 pregnant	 women	 with	 NGT,	 the	 insulinogenic	 index	 (insulin	
response	per	unit	of	glycaemic	 stimulus)	was	significantly	 lower	 in	GDM	pregnancies	
(40%)	compared	to	normal	pregnancies	(90%).		
It	 has	 been	 demonstrated	 that	 during	 both	 early	 and	 more	 profoundly	 in	 late	
pregnancy,	 the	 first	phase	 insulin	response	(insulin	released	 immediately	 in	response	
to	 elevated	 glucose	 levels	 as	 opposed	 to	 second	 phase	 response	 which	 is	 a	 slow	
continuous	 release	 independent	 upon	 glucose	 levels)	 is	 significantly	 reduced	 among	
women	with	GDM	when	compared	to	those	with	NGT[14].		
Buchanan	et	al	demonstrated	a	significant	reduction	in	first-phase	insulin	response	as	
well	 as	 a	 borderline-significant	 reduction	 in	 second-phase	 insulin	 secretion	 between	
GDM	 and	 control	 subjects,	 however	 no	 change	 in	 insulin	 sensitivity;	 concluding	 that	








As	mentioned	 previously,	 insulin	 resistance	 increases	 in	 all	 pregnancies.	 It	 has	 been	













This	 fall	 in	 insulin	 sensitivity	 is	 compensated	 for	 by	 a	 marked	 increase	 in	 first	 and	













Pregnancies	 in	 which	 the	 mother	 has	 GDM	 are	 at	 risk	 of	 a	 number	 of	 maternal	
complications	including	hypertensive	disease	and	risk	of	caesarean	section	[16].	It	has	
been	hypothesised	 that	 fetal	hyperinsulinaemia	 (to	 counteract	elevated	maternal	 and	
hence	 fetal	 circulating	 serum	 glucose	 levels)	 results	 in	 the	 following	 increased	 fetal	
risks	[17]:		
• Overgrowth	 of	 insulin-sensitive	 tissues	 such	 as	 adipose	 tissue,	 increasing	 the	
risk	of	 fetal	macrosomia,	 shoulder	dystocia,	perinatal	death,	birth	 trauma	and	
need	for	caesarean	section.	




	It	 has	 been	 demonstrated	 that	 with	 interventions	 including	 diet	 and	 exercise	
modification,	 blood	 glucose	 monitoring	 and	 insulin	 treatment,	 with	 the	 intent	 of	
achieving	euglycaemia,	 there	 is	a	 significant	 reduction	 in	 the	 risk	of	 serious	perinatal	
outcomes	(4%	versus	1%,	p=0.01)	[2].	
1.3	TREATMENT	OF	GDM	
The	 target	 of	 GDM	management	 is	 achieving	 euglycaemia	with	 a	 particular	 focus	 on	
reducing	 post-prandial	 episodes	 (at	 one	 and	 two	 hours)	 of	 hyperglycaemia	 as	 this	 is	















Table	 2:	 Scottish	 Intercollegiate	 Guidelines	 Network	 (SIGN)	 recommendations	 for	 targets	 of	
glycaemic	control	in	pregnancy	[19].	
Treatment	 of	 GDM	 currently	 begins	with	 dietary	modification	 and	 exercise	 advice.	 If	
this	 fails	 to	 achieve	 euglycaemia	 (approximately	 50%	 of	 cases)	 then	 treatment	 with	
medications	is	indicated.		
Traditionally	the	first-line	medical	treatment	in	the	UK	was	with	subcutaneous	insulin	
injections	[20].	Human	(maternal)	 insulin	does	not	cross	 the	placenta	due	to	 its	 large	
molecular	weight	(5808Da)	unless	 it	 is	bound	to	 IgG	[21].	 In	vivo	 studies	with	 insulin	
Lispro	 (Humalog),	 an	 insulin	 analogue,	 demonstrated	 no	 Lispro	 present	 in	 fetal	 cord	
blood	 [22].	 By	 contrast,	 in	 vitro	 studies	 using	 a	 placental	 perfusion	 model,	
demonstrated	 the	 presence	 of	 insulin	 at	 1-5%	 of	maternal	 concentration	 in	 the	 fetal	
compartment.	It	should	be	noted	that	this	was	at	concentrations	exceeding	those	seen	
in	the	maternal	circulation	when	insulin	is	administered	therapeutically	[21].		
A	 part	 of	 the	 physiological	 process	 behind	 GDM	 is	 a	 reduction	 in	 the	 insulinogenic	
response	 to	 glucose	 stimulus;	 it	 is	 therefore	 logical	 that	 supplemental	 insulin,	 either	
short	or	 long	acting,	will	elevate	circulating	insulin	levels.	 It	 is	through	these	elevated	
levels	that	the	reduction	in	insulin	sensitivity	seen	in	pregnancy	(both	in	NGT	women	
and	women	with	GDM)	can	be	overcome.	Various	studies	have	demonstrated	the	safety	








no	 adverse	 fetal	 outcomes	 associated	 with	 insulin	 therapy	 demonstrated	 in	 the	
literature.	
Whilst	insulin	is	well	established	in	its	ability	to	control	GDM,	there	has	been	a	drive	to	
find	 treatments	 that	 are	more	 acceptable	 to	 the	 patient,	more	 cost	 effective	 and	will	
also	 target	 the	 insulin	 resistance	 aspect	 of	 pregnancy	 that	 is	 exacerbated	 by	 the	
reduced	 insulin	 response	seen	 in	GDM.	As	a	 result	of	 this	attention	has	 turned	 to	 the	
use	 of	 oral	 hypoglycaemic	 agents	 (OHAs)	 in	 pregnancy,	 with	 particular	 interest	 in	
metformin	and	glibenclamide	(glyburide).		
Metformin	 comes	 from	 the	 biguanide	 class	 of	 medications,	 increasing	 peripheral	




potassium	 channel	 receptors	 in	 the	 β-islets	 cells	 of	 the	 pancreas	 to	 enhance	
endogenous	insulin	secretion	[27].	
In	 the	 last	 decade	 several	 trials	 have	 demonstrated	 the	 safety	 and	 efficacy	 for	
controlling	hyperglycaemia	with	metformin	and	glibenclamide	[28-33]	in	GDM.		
The	 efficacy	 of	 glibenclamide	 (at	 a	 maximum	 dose	 of	 20mg	 daily)	 was	 compared	 to	
insulin	 in	 a	 study	 involving	 404	 women	 with	 GDM;	 only	 4%	 of	 women	 required	










The	Metformin	versus	 Insulin	 for	 the	 treatment	of	Gestational	diabetes	 (MiG)	 trial	was	
the	first	large	randomised	controlled	trial	(RCT)	comparing	the	use	of	metformin	with	
insulin	 in	GDM	 [30]	with	 the	women	 receiving	 between	500	 and	2500mg	metformin	
daily.	 This	 trial	 used	 a	 composite	 of	 neonatal	 outcomes	 and	 they	 demonstrated	 no	
difference	 in	 adverse	 outcomes	 between	 the	 metformin	 group	 and	 insulin	 group	
(32.0%	 and	 32.2%	 respectively,	 RR	 0.99,	 95%	 CI,	 0.80	 –	 1.23).	 Among	 the	 women	
assigned	to	metformin,	46.3%	required	additional	insulin	therapy.		
A	comparative	study	between	metformin	and	glibenclamide	 in	150	women	with	GDM	
demonstrated	 no	 difference	 between	 1hr	 postprandial	 glucose	 values,	 rates	 of	
preeclampsia	 or	 maternal	 hypoglycaemia.	 34.7%	 of	 patients	 receiving	 metformin	
required	additional	insulin	therapy,	in	comparison	to	16.2%	in	the	glibenclamide	group	
(p=0.01)[35].	 The	mean	birth	weight	 of	 babies	 from	 the	metformin	 group	was	 lower	
than	that	from	the	glibenclamide	group	(3103g	±600g	versus	3329g	±334g,	p=0.02)	but	
otherwise	 there	was	 no	 difference	 in	 neonatal	 outcomes.	Whilst	 the	 requirement	 for	




line	with	 insulin	 therapy.	 In	 these	 trials	 the	 range	 of	metformin	 taken	was	 between	
500mg	 (one	 tablet)	 and	 2500mg	 daily	 and	 the	 range	 of	 glibenclamide	 dosing	 was	
between	2.5mg	(one	tablet)	and	20mg	(four	5mg	tablets)	daily.	In	the	MiG	trial	1.9%	of	
participants	 had	 to	 stop	 treatment	 due	 to	 gastrointestinal	 (GI)	 side	 effects	 and	 8.8%	









although	 the	 side	 effect	 profile	 is	 thought	 to	 be	 similar	 to	 that	 of	metformin.	 In	 this	











Metformin	 is	 a	 small,	 basic	 compound	 and	 as	 a	 substrate	 for	 organic	 cation	
transporters	 (OCTs)	has	been	shown	 to	 cross	 the	placenta	 [36]	 in	a	 carrier-mediated	
fashion	 rather	 than	 by	 passive	 diffusion	 [37].	 The	 level	 to	 which	 it	 passes	 and	 the	
concentrations	 that	 it	 can	 build	 to	 in	 fetal	 blood	 is	 controversial.	 In	 vivo	 data	 has	
demonstrated	cord	blood	levels	to	be	60%	that	of	maternal	levels;	taken	from	23	babies	
whose	mothers	took	metformin	(median	daily	dose	2000mg)	through	their	pregnancy	
[38].	 However,	 this	 study	 only	 measured	 maternal	 metformin	 levels	 in	 seven	 of	 the	
women	 and	 the	 samples	 were	 taken	 at	 different	 times	 in	 relation	 to	 last	 metformin	
dose;	 cord	blood	on	 average	10	hours	 since	 last	metformin	dose	 and	maternal	 blood	
4.5hours	 after	 last	 dose.	 The	 half-life	 of	 metformin	 is	 between	 1.5	 and	 4.5	 hours,	
meaning	 this	 study	may	have	under-estimated	 the	 level	 of	 fetal	metformin	 exposure.	
Another	study	demonstrated	levels	higher	in	cord	blood	than	maternal	blood	(up	to	2	
times	increased)	although	this	study	is	also	limited	by	a	small	sample	size	(n=15)	[39].	
It	 has	 been	 hypothesised	 that	 fetal	 levels	 may	 exceed	 maternal	 levels	 due	 to	 fetal	
reabsorption	of	the	metformin	(from	amniotic	fluid)	or	due	to	maternal	excretion	[40].		
In	contrast	 to	 the	 in	vivo	data	above,	an	 in	vitro	study	using	placental	dual	perfusion	
studies	demonstrated	 that	metformin	crosses	 into	 the	 fetal	circulation,	with	a	 fetal	 to	
maternal	 concentration	 ratio	 of	 0.51	 ±	 0.15	 (mean	 ±	 SD)	 [40].	 In	 keeping	with	 other	
studies	they	demonstrated	equal	 levels	between	umbilical	artery	and	vein,	suggesting	
minimal	 distribution	 and	 metabolism	 of	 metformin	 by	 the	 fetus.	 The	 difference	













for	 fetal	survival	 [41].	Vanky	et	al	demonstrated	that	 fetal	exposure	to	metformin	did	
not	 appear	 to	 alter	 umbilical	 blood	 pH	 (metformin	 has	 been	 known	 to	 induce	 lactic	
acidosis	in	adults)	or	cause	teratogenicity,	however	recommended	further	longitudinal	
studies	to	look	for	long	term	effects	of	metformin	on	the	fetus	[39].	
Initial	 studies	 looking	 at	 whether	 glibenclamide	 crossed	 into	 the	 fetal	 circulation	
suggested	 that	 any	 transfer	 was	 negligible;	 this	 was	 attributed	 to	 the	 thought	 that	
glibenclamide	 is	predominately,	99.8%,	protein	bound	and	coupled	with	a	 short	 (six-
hours)	 half-life	 makes	 for	 a	 very	 small	 amount	 of	 free	 drug	 available	 for	 placental	
transfer	 [28,	 42,	 43].	 However,	 with	 the	 development	 of	 more	 specific	 methods	 for	
detecting	glibenclamide	at	lower	concentrations	(for	example	high-performance	liquid	
chromatography	 mass	 spectrometry	 assays	 with	 a	 limit	 of	 quantitation	 (LOQ)	 of	
0.25ng/ml)	it	has	emerged	that	it	does	in	fact	cross	the	placenta	to	some	extent.	
In	 a	 recent	 study	 of	 40	 pregnant	 women	 with	 GDM	 treated	 with	 glibenclamide,	 the	
presence	of	glibenclamide	in	cord	blood	was	demonstrated,	at	levels	on	average	70%	±	
40%	that	of	the	concentration	in	maternal	serum	[44].	Further	studies	have	shown	that	
glibenclamide	crosses	 into	 the	placental	 circulation	via	diffusion,	however,	much	of	 it	
never	 reaches	 the	 fetal	 circulation	 as	 a	 result	 of	 a	 network	 of	 placental	 apical	
membrane	 transporters	 which	 actively	 efflux	 the	 drug	 back	 into	 the	 maternal	







present	 in	 the	 fetal	 circulation	 has	 been	 shown	 to	 be	 transported	 against	 a	
concentration	 gradient	 into	 the	 maternal	 circulation	 [49].	 These	 transporters	 are	
thought	 to	 play	 a	 key	 role	 in	 protecting	 the	 fetus	 from	 unwanted	 endogenous	





umbilical	 cord),	 bringing	 the	 fetal	 and	 maternal	 circulations	 into	 close	 contact.	 The	
placenta	 has	 many	 functions	 including	 supply	 of	 nutrition	 to	 the	 fetus,	 removal	 of	





called	 cotyledons)	 and	 fetal	 tissues	 (forming	 the	 chorionic	 plate	 and	 chorionic	 villi).	
The	functional	unit	of	the	placenta	is	the	syncytiotrophoblast	(ST)	that	is	formed	by	the	











































It	 is	often	necessary	 to	give	medications	 to	a	woman	during	her	pregnancy	 to	 treat	a	
variety	of	conditions,	such	as	GDM.	It	is	the	ability	of	many	drugs	to	act	as	substrates	to	






The	 ABC	 transporter	 super-family	 plays	 a	 crucial	 role	 in	 many	 important	 biological	





important	 role	 in	 protecting	 various	 sites	 such	 as	 the	 brain,	 testis	 and	 fetus	 from	
pharmacological	influences	[62].	It	is	this	role	of	protecting	the	fetus	from	the	effect	of	
xenobiotics	 [46,	 47]	 that	 this	 review	 will	 be	 focusing	 on,	 with	 particular	 interest	 in	




























P-gp	 is	 a	 170kDa	 membrane	 protein	 first	 discovered	 in	 1976	 in	 Chinese	 hamster	
ovarian	 tissue	 [63].	 P-gp	 acts	 to	 extrude	 a	 large	 number	 of	 substances	 from	 the	
syncytiotrophoblast,	 typically	 favouring	 hydrophilic	 positively	 charged	 compounds	
[64].	
Evidence	of	placental	P-gp	presence	
The	 presence	 of	 P-gp	 protein	 in	 the	 placental	 trophoblast	 was	 first	 demonstrated	
through	 immunohistochemistry	 in	 1988	 and	 again	 in	 1990	 [61,	 65].	 Since	 then	



























66-68].	 Whilst	 carrying	 out	 functional	 testing	 of	 placental	 P-gp	 in	 placental	 brush	
border	membrane	vesicles	and	basal	membrane	vesicles,	Ushigome	et	al	demonstrated	
that	 P-gp	 is	 located	 on	 the	 maternal	 surface	 of	 the	 trophoblasts	 (brush	 border	
membrane)	 and	 not	 the	 basal	membrane	 [69].	 This	was	 confirmed	 by	Atkinson	 et	al	
[67],	 suggesting	 that	 the	 maternal	 brush	 border	 membrane	 plays	 an	 active	 role	 in	





trimester	 placentas	 was	 demonstrated	 [70].	 This	 was	 confirmed	 through	 the	 use	 of	
real-time	 PCR	 and	 western	 blot	 analysis,	 demonstrating	 a	 significant	 difference	 in	
placentas	 from	the	 first	and	second	 trimesters	compared	 to	 term	at	both	protein	and	
mRNA	 level	 [71].	 A	 further	 study	 also	 confirmed	 these	 findings,	 using	 real-time	PCR,	
western	 blot	 analysis	 and	 ELIZA,	 showing	 P-gp	 levels	 44.8-fold	 higher	 at	 60-90	 days	
gestation	compared	to	term	placentas	(p<0.05)	[72].		














mdr1a	 -/-	 knockout	 mice,	 25%	mdr1a	 +/+	 and	 50%	 heterozygous	mdr1a	 +/-)	 they	
examined	the	impact	of	antenatal	exposure	to	avermectin	(known	to	cause	cleft	palate	
malformation	in	fetus).	They	found	that	fetuses	that	had	a	P-gp	genotype	of	-/-,	100%	




A	 recent	 review	 addressed	 the	 use	 of	 mouse	 models	 for	 human	 placental	 transport	
studies	 [73].	 Both	 human	 and	 mouse	 placentas	 are	 haemochorial	 type	 (i.e.	 fetal	
trophoblast	tissue	is	bathed	in	maternal	blood)	[74]	and	whilst	there	may	be	structural	
differences,	it	would	appear	that	there	are	also	significant	similarities.	Whilst	there	are	
two	 additional	 layers	 of	 trophoblast	 in	 the	 mouse	 placenta	 compared	 to	 the	 human	
placenta,	it	has	been	demonstrated	through	the	use	of	electron	microscopy	and	alkaline	




have	 a	 large	 impact	 upon	 permeability	 and	 thus	 the	 utility	 of	 the	 mouse-model	 for	
transport	 studies	 [76].	 Whilst	 mouse-models	 can	 provide	 a	 useful	 means	 for	
performing	 in	vivo	studies	 to	 look	at	 the	activity	of	ABC	 transporters	 in	 the	placenta,	
the	results	cannot	necessarily	be	extrapolated	directly	to	human	studies.	
In	vitro	studies	









into	 the	 fetal	 compartment	 was	 significantly	 increased	 (more	 than	 twice,	 P<0.01)	
compared	to	controls	highlighting	the	fact	that	the	P-gp	transporter	is	ATP-dependent.	
Through	 the	use	of	P-gp	 inhibitors	 it	was	demonstrated	 that	 the	amount	of	 substrate	




P-gp	 substrate	 into	 the	 fetus	 (p<0.01).	This	was	 confirmed	 in	a	 study	using	placental	
vesicles	and	hydatidiform	mole	tissue;	the	presence	of	P-gp	in	placental	tissue	and	the	






















BCRP	 has	 been	 shown	 to	 be	 expressed	 in	 high	 levels	 in	 placental	 tissue	 both	 using	




There	 is	 a	 discrepancy	 in	 the	 evidence	 regarding	 the	 expression	 of	 BCRP	 through	
gestational	age.	A	quantitative	study	into	the	expression	(protein	and	mRNA)	of	BCRP	
demonstrated	through	both	ELISA	and	Western	Blot	Analysis	that	placental	expression	




to	 these	 studies,	 a	 further	 study	 demonstrated	 a	 trend	 similar	 to	 that	with	 P-gp:	 the	
BCRP	mRNA	 levels	 in	 human	 preterm	 placentas	 (28	 ±	 1	 weeks,	 15	 placentas)	 were	
approximately	two	times	higher	than	that	at	term	(39	±	2	weeks,	29	placentas),	p<0.05	
[85].	 The	 reasons	 behind	 the	 variation	 in	 the	 results	 between	 the	 studies	 is	 unclear,	
although	 the	 first	 two	 studies	 both	 had	 much	 smaller	 sample	 sizes	 than	 the	 latter,	
although	that	study	only	looked	at	per-term	and	term	placentas	and	not	placentas	from	
early	pregnancy.	The	data	from	rodent	studies	is	consistent	with	that	found	in	the	latter	












Jonker	et	al	 carried	out	 the	 first	 in	vivo	 transport	 study	demonstrating	 the	activity	of	
BCRP	in	the	placenta	[87].	They	used	P-gp	deficient	mice	(by	excluding	this	transporter,	
they	 were	 ensuring	 that	 the	 BCRP	 substrate	 used	 would	 need	 to	 be	 transported	 by	
BCRP	alone)	and	exposed	them	to	GG918	(a	BCRP	inhibitor).	They	then	measured	the	
distribution	 of	 topotecan	 (a	 BCRP	 substrate)	 in	 the	 fetuses	 and	 found	 a	 two-fold	
increase	compared	to	vehicle-treated	mice	(P<0.01).			
This	work	was	 confirmed	 in	 a	 study	 looking	 at	 the	 accumulation	 of	 glibenclamide	 in	
Bcrp1	-/-	pregnant	mice	and	wild-type	mice.	They	demonstrated	that	the	concentration	




1	placental	cell	 lines	(express	BCRP	but	not	P-gp)	 that	BCRP	effluxed	substrates	 from	




MRP2	expression)	were	used	 to	 show	 that	 inhibition	of	BCRP	 transporters	 increased	
the	 intracellular	 accumulation	 of	MX	 fluorescence	 two-fold	 (p<0.01)	 [88].	 This	 study	








of	 a	 BCRP	 inhibitor,	while	 there	was	 no	 difference	 in	maternal	 to	 fetal	movement	 of	
glibenclamide	(p<0.005).	
Gedeon	 et	 al	 used	 in-side	 out	 membrane	 vesicles	 from	 human	 placental	 tissue	 to	




The	MRP	 family	was	 discovered	 in	 1992	 initially	 by	 Cole	 et	al	who	 identified	MRP-1	
[91].	Gradually	over	the	ensuing	six	years	the	other	members	of	the	family	(MRP	1-7)	
were	 identified	 [92-96].	 The	 corresponding	 sequences	 for	 these	 members	 were	
identified	 by	 Allikmets	 et	 al	 in	 1996	 [97].	 MRP	 proteins	 mediate	 ATP-dependent	







St-Pierre	 et	al	 localised	MRP1	 to	 the	 fetal	 endothelial	 cells,	 a	 finding	 consistent	with	
Nagashige	 et	 al	who	 used	 Western	 blotting	 analysis	 and	 immunohistochemistry	 to	
demonstrate	 this.	They	were	also	able	 to	 localise	MRP1	 further	 to	 the	 luminal	side	of	
the	 fetal	 blood	 endothelial	 cells	 in	 the	 villi	 [100].	 Where	 St-Pierre	 and	 Nagashige	










[101].	 A	 further	 study	 using	 western	 blotting	 and	 immunohistochemistry	 staining		
showed	 the	 optical	 density	 (on	western	 blotting	with	 densitometry)	 of	MRP1	 on	 the	
basolateral	membrane	 to	 be	 8.8	 ±	 1.4	 compared	 to	 2.3	 ±	 0.3	 (p<0.005)	 on	 the	 brush	
border	membranes	[67].		
MRP	expression	through	gestation	
Pascolo	et	 al	performed	PCR	studies	 looking	at	MRP	expression	 in	placental	 tissue	at	
different	 gestations	 [99].	 MRP	 1	 expression	 has	 been	 shown	 to	 increase	 through	
gestation,	 with	 levels	 four-fold	 greater	 in	 the	 third	 trimester	 compared	 to	 the	 first	
trimester	(p<0.0001).	Levels	of	MRP2	also	increased	two-fold	with	gestation,	(4.9	±	0.6	
(term)	 vs.	 2.65	 ±	 0.3	 (early	 gestation),	 p	 <	 0:004).	 By	 comparison,	 there	 was	 no	




were	 used	 to	 demonstrate	 that	 [3H]	 vinblastine	 (a	 MRP	 1	 substrate)	 transport	 was	
inhibited	 in	 the	 presence	 of	 cyclosporine	 A	 (a	 MRP	 1	 inhibitor)	 leading	 to	 an	
intracellular	accumulation	of	[3H]	vinblastine	(p<0.0001).[67].		
A	 study	 looking	 at	 the	 transport	 of	 three	 OHAs	 (rosiglitazone,	 glibenclamide	 and	
metformin)	demonstrated	the	transport	of	glibenclamide	via	MRP1	transporters	in	the	
presence	of	 inhibitors	of	P-gp	and	BCRP	 [102].	The	results	 from	this	 study	should	be	











	St-Pierre	 et	 al	 also	 performed	 transport	 studies	 showing	 the	 uptake	 of	 two	 MRP	
substrates	([3H]estradiol–17-β	and	DNP-SG).	They	performed	the	uptake	studies	in	the	





lines	 [90];	 in	MRP3	 transfected	cells	 there	was	a	1.8-fold	 increase	 in	accumulation	of	
glibenclamide	 in	 the	presence	of	 indomethacin	 (an	MRP	 inhibitor)	 (p<0.05)	whilst	 in	
MRP1	 transfected	 cells	 the	 opposite	 was	 true,	 with	 reduced	 accumulation	 of	
glibenclamide	 in	 the	 presence	 of	 indomethacin.	 This	 has	 also	 been	 demonstrated	 for	
MRP	3	and	MRP	1	and	2	through	other	studies	[99,	103].	However,	in	2008	Gedeon	et	al	
used	 a	 dually	 perfused	 placental	 model	 to	 study	 the	 efflux	 of	 glibenclamide	 in	 the	
presence	of	Indomethacin	(an	MRP	inhibitor)	[104].	Interestingly	this	work	showed	no	
change	 in	 the	 transport	 of	 glibenclamide	 in	 the	 presence	 of	 indomethacin	 in	 tissues	
with	 biologically	 relevant	 levels	 of	 the	 transporters	 (unlike	 studies	 using	 over-














































direction	 than	 vice	 versa.	 An	 in	 vitro	 study	 using	 placental	 brush	 border	 inside-out	
vesicles	examined	the	importance	of	the	three	main	ABC	transporters	on	the	efflux	of	
metformin	 [102].	 Through	 the	 use	 of	 inhibitors	 of	 P-gp,	 BCRP	 and	 MRP	 they	
demonstrated	 the	 role	 these	 different	 transporters	 play	 in	 the	 efflux	 of	 metformin,	
showing	that	P-gp	transports	 the	majority	of	metformin,	with	BCRP	also	 transporting	
some,	when	 all	 three	 transporters	were	 inhibited,	 the	 transport	 of	metformin,	 to	 the	








Figure	 6:	 The	 relative	 contributions	 of	 P-gp,	 BCRP	 and	 MRP1	 to	 metformin	 efflux	 from	 the	 fetal	 to	
maternal	 compartment,	 determined	 using	 chemical	 inhibition	 of	 ATP-dependent	 transport	 of	 100nM	
[14C]-metformin	in	placental	inside	out	vesicles	(IOVs)	(pool	of	60	preparations).	Adapted	from	Hemauer	
S.J.	et	al	2010	[102]		
Compared	 to	 metformin	 there	 have	 been	 numerous	 studies	 looking	 at	 the	 efflux	 of	
glibenclamide	 across	 the	 placenta.	 Glibenclamide	 is	 highly	 lipophilic	 and	 like	
metformin	has	a	low	molecular	weight.	Kraemer	et	al	provided	the	first	evidence,	using	
a	 dual	 perfusion	 of	 placental	 lobule	 (DPPL)	 technique	 with	 glibenclamide	 in	 both	
maternal	 and	 fetal	 circulations,	 that	 glibenclamide	 is	 actively	 extruded	 from	 the	 fetal	
circulation	 into	 the	 maternal	 circulation	 even	 against	 a	 concentration	 gradient	 [45].	
They	 also	 carried	 out	 a	 parallel	 study	 in	 the	 presence	 of	 Verapamil,	 a	 known	 P-gp	
inhibitor,	and	demonstrated	that	this	did	not	affect	glibenclamide	transport,	suggesting	
another	placental	transporter	transports	the	glibenclamide.	












and	3	 as	well	 as	 the	other	ABC	 transporters.	 It	 is	 important	 to	note	 thought	 that	 the	
concentration	of	glibenclamide	to	bring	about	this	effect	was	significantly	higher	than	
any	 therapeutic	 level	 (in	 the	 experiment	 they	 used	 a	 concentration	 of	 98,800ug/L	
(200uM)	 whilst	 clinically	 the	 upper	 limit	 of	 glibenclamide	 measured	 in	 serum	 is	
150ug/L).		
Zhou	et	al	performed	the	first	in	vivo	studies,	using	a	mouse	model,	to	demonstrate	the	
efflux	 of	 glibenclamide	by	BCRP,	with	 fetal	 levels	 of	 glibenclamide	 two-fold	higher	 in	
BCRP1-/-	mice	compared	to	wild-type	(p<0.01)	[88].	Again	they	confirmed	the	finding	
of	 previous	 studies	 that	 at	 doses	 far	 above	 those	 achieved	 therapeutically,	
glibenclamide	is	an	inhibitor	of	the	ABC	transporters.	Pollex	et	al	provided	the	first	 in	
vitro	 evidence	 using	 DPPL	 that	 BCRP	 actively	 effluxes	 glibenclamide	 [107].	
Interestingly,	 the	use	of	nicardipine,	 a	BCRP	 inhibitor,	was	able	 to	partially	block	 the	
transfer	of	glibenclamide	across	the	placenta	but	not	entirely,	suggesting	the	presence	





no	 difference	 between	 the	 groups	 [49].	 Anger	 et	 al	 examined	 the	 expression	 of	 ABC	
transporters	in	placentas	from	women	with	GDM,	Type	1	diabetes	(both	groups	insulin	
treated)	and	 those	without	diabetes	 (35	placentas	 included	 in	study)	using	qPCR	and	
Western	 Blotting	 [108].	 They	 demonstrated	 that	 at	 the	 mRNA	 level,	 there	 were	
significantly	 increased	 levels	 of	 MDR1	 (P-gp)	 in	 the	 GDM	 (on	 insulin)	 group	 (n=13)	







(p<0.05).	 Interestingly	 though	 this	 did	 not	 translate	 to	 protein	 expression	 with	 no	
difference	 detected	 between	 the	 groups	 for	 any	 of	 the	 ABC	 transporters	 examined	
(BCRP,	 P-gp	 and	 MRP2)(p>0.05).	 However;	 within	 the	 diabetic	 groups	 there	 was	 a	
positive	 correlation	 between	maternal	 HbA1c	 level	 (a	measure	 of	 glycaemic	 control)	
and	 BCRP	mRNA	 and	 protein	 expression	 suggesting	 that	 levels	 change	 with	 glucose	
control(r=0.58,	p<0.01).	A	 criticism	of	 this	 study	 is	 that	no	effort	was	made	 to	match	
the	 samples	 for	 gestation	 or	 BMI	 and	 there	was	 a	 significant	 difference	 between	 the	
BMI	of	 the	GDM	group	and	 that	of	 the	control	group	(controls:	23.2	±	4.5,	GDM:	29	±	
6.6,	p<0.05).	
2.6	CONCLUSIONS	
GDM	 is	 increasing	 in	 prevalence	 and	 the	 drive	 to	 develop	 treatments	 that	 are	
acceptable	 to	 the	 women,	 more	 cost	 effective	 and	 achieve	 euglycaemia	 whilst	 not	
compromising	 fetal	 safety	 is	 increasing.	 Clinical	 trials	 have	 been	 carried	 out	
demonstrating	 the	 efficacy	 of	metformin	 and	 glibenclamide	 in	 the	 treatment	 of	 GDM	
compared	 to	 insulin	 and	 also	 demonstrated	 no	 adverse	 fetal	 outcomes	 with	 these	
treatments.	These	have	both	now	become	commonly	used	treatments.	
The	 presence	 of	 ABC	 transporters	 in	 the	 placenta	 is	 now	well	 documented	 although	
there	 are	 discrepancies	 in	 the	 evidence,	 particularly	 regarding	 the	 location	 of	 the	
individual	transporters	and	their	expression	through	gestation.	There	is	some	in-vitro	
evidence	 regarding	 the	 efflux	 of	metformin	 from	 the	 fetal	 to	maternal	 circulation	 via	
the	 P-gp	 transporters.	 There	 is	 far	 more	 evidence	 regarding	 the	 transport	 of	
Glibenclamide,	 with	 the	 body	 of	 evidence	 suggesting	 that	 it	 is	 predominately	















would	 be	 interesting	 to	 examine	 the	 impact	 of	 combined	 therapy	 on	 the	 ABC	
transporters	involved	in	effluxing	them	from	the	fetal	circulation	as	this	is	a	treatment	











As	 mentioned	 above,	 there	 is	 scanty	 evidence	 regarding	 the	 effect	 of	 gestational	
diabetes	on	the	ABC	transporters	with	the	study	by	Anger	et	al	showing	some	impact	
among	a	small	cohort	of	placentas	in	insulin-treated	patients.	Despite	a	lot	of	research	
into	 the	 safety	 of	 oral	 hypoglycaemic	 agents	 (OHA’s)	 for	 the	 treatment	 of	 GDM,	 and	
work	 demonstrating	 the	 importance	 of	 the	 ABC	 transporters	 for	 effluxing	 these	
medications	 away	 from	 the	 fetal	 circulation,	 there	 is	 a	 distinct	 lack	 of	 evidence	
regarding	 the	 impact	 of	 GDM	 and	 the	 OHA’s	 used	 to	 treat	 it	 on	 the	 transporters	
themselves.		
















This	 hypothesis	 is	 based	 upon	 the	 results	 from	 the	 Anger	 et	 al	 study	 [108]	 that	 had	
















minutes	 at	 full	 speed	 and	 the	 supernatant	 removed	 and	 placed	 in	 a	 new	 2.0ml	
Eppendorf	 tube.	 Total	 RNA	 was	 then	 isolated	 using	 the	 Qiagen	 RNeasy	 mini-kits	
(Qiagen,	 Australia)	 using	 the	 following	method.	 The	RNA	was	 precipitated	 out	 of	 the	
lysate	into		a	RNeasy	spin	column	using	600uL	70%	ethanol	and	centrifuged	for	1min	at	











350uL	 buffer	 RW1	 (centrifuged	 for	 1	 minute	 at	 ≥10,000rpm	 again)	 to	 remove	 any	
material	not	well	bound	to	the	spin	column,	prior	to	a	DNase	step	being	performed	to	
remove	any	genomic	DNA	present.	70uL	buffer	RDD	was	added	to	10uL	DNase	1	stock	
solution	 (gentle	 pipette	 mixing	 the	 samples,	 avoiding	 vigorous	 shaking	 as	 this	 can	
denature	 the	 enzyme)	 and	 then	 added	 to	 the	 spin	 column	membrane	 and	 left	 for	 30	
minutes	at	room	temperature.	Further	washes	were	then	performed,	first	with	350uL	
RW1	 buffer,	 centrifuged	 for	 1	 minute	 at	 ≥10,000rpm	 (flow-through	 discarded)	 and	
then	 with	 500uL	 RPE	 buffer	 and	 centrifuged	 for	 	 1	 minute	 at	 ≥10,000rpm	 (flow-
through	 discarded).	 This	 RPE	 buffer	 step	 was	 then	 repeated	 and	 centrifuged	 for	 2	
minutes	 at	 ≥10,000rpm;	 the	 RPE	 buffer	 contains	 ethanol	 therefore	 acts	 to	wash	 and	
precipitate	RNA	to	release	it	from	the	column	but	not	wash	it	through	(i.e.	loosens	it).	
The	 spin	 column	 was	 then	 removed	 and	 placed	 in	 a	 new	 2ml	 collection	 tube	 and	
centrifuged	 for	 1	minute	 at	 ≥10,000rpm	 to	 ensure	 all	wash	 solutions	were	 removed.	
The	column	was	then	placed	in	a	1.5ml	Eppendorf	tube	and	RNA	extraction	performed	
by	 adding	 50uL	 RNase-free	 water	 directly	 to	 the	 spin	 column	 and	 centrifuged	 for	 1	
minute	 at	 ≥10,000rpm,	 the	 flow-through	 was	 retained	 as	 this	 now	 contained	 the	
extracted	RNA	which	has	been	eluted	 from	the	column	by	 the	RNase-free	water.	This	
step	was	 then	 repeated	 to	 ensure	 all	RNA	was	 removed.	A	Nanodrop	1000	was	 then	
used	 to	 check	 the	 quality	 of	 the	 RNA	 and	 calculate	 the	 concentration	 of	 total	 RNA	
(ng/uL),	 using	 2uL	 samples	 of	 the	 RNA	 extracted,	 ensuring	 that	 the	 Nanodrop	 was	



















	 RT	pos	(uL)	 RT	neg	(uL)	 RT	pos	(uL)	 RT	neg	(uL)	
10	x	RT	buffer	 2	 2	 5	 5	
25	x	dNTPs	 0.8	 0.8	 2	 2	
10	x	random	
primers	
2	 2	 5	 5	
Reverse	
transcriptase	
1	 nil	 2.5	 Nil	
RNase	inhibitor	 1	 1	 2.5	 2.5	
DEPC	water	 3.2	 4.2	 8	 10.5	
	
Table	4:	Quantities	of	different	components	for	making	cDNA	mastermix.	
The	 amount	 of	 RNA	 (uL)	 needed	 to	 get	 a	 concentration	 of	 1ug/uL	 was	 calculated	
(=1000/concentration	 RNA	 in	 sample	 from	 nanodrop(ng/uL)).	 This	 amount	 of	 RNA	
from	 each	 sample	 was	 added	 to	 labelled	 0.2ml	 Eppendorf	 tubes;	 for	 20uL	 reactions	
enough	 RNase-free	water	was	 added	 to	make	 up	 to	 10uL,	 for	 50uL	 reaction	 enough	
RNase-free	water	was	added	to	make	up	to	25uL.	Mastermix	was	added	to	each	tube;	if	
10uL	mastermix	for	the	20uL	reactions	and	25ul	mastermix	for	the	50uL	reaction.	NB	
at	 this	 point	 RT	 negative	 mastermix	 was	 added	 to	 the	 correct	 tubes	 labelled	 RT	













endogenous	 controls,	 looking	 for	 consistency	 between	 diabetic	 and	 non-diabetic	
samples:	18S,	YWHAZ	and	β-ACTIN.	YWHAZ	was	chosen	 for	use	due	 to	 its	 consistency	
between	diabetic	 and	non-diabetic	 samples	 and	 also	 it	 diluted	out	 appropriately	 at	 a	
1in10	 dilution.	 To	 standardise	 across	 all	 the	 PCR	 plates,	 I	 ran	 the	 same	 non-diabetic	
control	sample	on	each	plate.	
Pre-designed,	 validated	 gene-specific	TaqMan®	MGB	FAM	 labelled	primer	 and	probe	
sets	 were	 used	 for	 YWHAZ	 (Hs03044281_g1),	 ABC	 B1	 (Hs00184500_m1),	 ABC	 C3	
(Hs00978473_m1)	and	ABC	G2	(Hs01053790_m1).		The	components	for	mastermix	and	
cDNA	samples	were	thawed	on	ice.	A	mastermix	was	made	for	each	primer/probe	in	a	
2.0ml	 Eppendorf	 tube,	 using	 10uL	 of	 TAQman	 universal	 mastermix	 II	 (Applied	
Biosystems)	 with	 1uL	 of	 primer/probe	 solution	 and	 8uL	 of	 nuclease-free	 water	
(enough	 multiples	 of	 this	 was	 made	 for	 each	 primer/probe	 for	 each	 sample	 being	





relevant	 gene.	An	example	 layout	of	 a	PCR	plate	 template	 is	 given	below.	 If	 the	plate	












The	 PCR	 reaction	 was	 performed	 in	 the	 TaqMan	 7900	 HT	 PCR	 machine	 (Applied	
Biosystems)	after	spinning	the	plate	 in	a	centrifuge	for	1	minute	at	1000rpm.	 	To	run	
the	 PCR	 reaction	 the	 following	was	 done:	 The	 SDS	 2.4	 programme	was	 opened,	 new	
assay	 standard,	 384	well	 plate	 selected.	 All	 wells	with	 same	 colour	 detector	 –	 ACTB	
FAM	for	all	the	assays	used	for	the	above	reactions,	were	selected	and	this	was	copied	
to	 the	plate.	Empty	wells	were	highlighted	and	 “omit	wells”	 selected.	The	 instrument	
tab	 was	 opened,	 sample	 volume	 set	 to	 20uL	 and	 the	 realtime	 tab	 selected	 prior	 to	
highlighting	the	whole	plate.	The	“connect	to	instrument”	tab	was	pressed	and	the	PCR	
plate	 was	 inserted	 into	 the	 machine	 prior	 to	 pressing	 “start	 run”	 tab.	 Changes	 to	



















and	 Ct	 values	 averaged	 (all	 samples	 were	 run	 in	 triplicate).	 The	 relative	 expression	
values	were	 calculated	 normalising	 for	 the	 endogenous	 control	 (YWHAZ)	 and	 for	 the	
internal	control	sample	(a	non-diabetic	sample	which	was	run	on	every	PCR	plate).		
GraphPad®	Prism	6	was	used	to	perform	statistical	analysis	and	draw	figures.		Normal	
distribution	was	 tested	 using	 a	 Shapiro-Wilk	 normality	 test	 and	 differences	 between	
groups	were	tested	using	unpaired	t-tests	for	continuous	variables	and	chi-squared	test	





approximately	 5minutes	 to	 cool	 them	 and	 the	 centrifuge	 was	 set	 to	 4˚C.	 1	 protease	
inhibitor	(Roche)	tablet	was	added	to	10ml	RIPA	buffer	(Sigma-Aldrich)	and	mixed	by	
hand.	 Approximately	 30mg	 of	 placental	 tissue	was	 placed	 in	 a	 2.0ml	 Eppendorf	 tube	
with	 a	 silver	 bead	 and	 500uL	 RIPA	 buffer.	 The	 tissue	 was	 then	 homogenised	 in	 the	
cooled	plates	of	the	Qiagen	Tissue	Lyser	at	25Hz	for	3	minutes	(run	twice	giving	a	total	














dilution2)	 and	 standards	 were	 added	 to	 the	 relevant	 wells	 in	 duplicate;	 an	 example	
plate	layout	is	outlined	below.	25uL	of	working	reagent	A	(20µL	reagent	S	to	each	1ml	
reagent	 A	 needed	 for	 assay)	 was	 added	 to	 each	 well	 on	 the	 plate	 and	 then	 200µL	
reagent	B	was	added	to	each	well	using	multichannel	pipette.	This	was	then	incubated	
on	 the	 bench	 for	 15minutes	 (timed)	 prior	 to	 quantification	 being	 performed	 using	 a	
Molecular	 Devices	 Thermomax	microplate	 reader	 at	 650nm-750nm	and	 Softmax	 Pro	
software.		
	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
A	 1.37mg/ml	 Sample	D	 	 	 	 	 	 	
B	 0.685mg/ml	 Sample	E	 	 	 	 	 	 	
C	 0.342mg/ml	 Sample	F	 	 	 	 	 	 	
D	 0.171mg/ml	 Sample	G	 	 	 	 	 	 	
E	 BLANK	 Sample	H	 	 	 	 	 	 	
F	 Sample	A	 Sample	I	 	 	 	 	 	 	
G	 Sample	B	 Sample	J	 	 	 	 	 	 	



















calculate	 the	 volume	 of	 supernatant	 required	 to	 give	 a	 4mg/mL	 concentration	 of	





3.5uL	 added	 to	 each	 0.2ml	 Eppendorf.	 The	 appropriate	 amount	 of	 protein	 and	 pure	
water	 (calculated	 as	 above	 to	 give	 4mg/ml	 concentration	 and	 total	 volume	of	 6.5uL)	
were	then	added	to	each	tube	prior	to	vortexing	for	5	seconds	and	then	centrifuging	for	
1	minute	at	≥10,000rpm	 .	Samples	were	 then	placed	 in	 the	G	storm	 for	10minutes	at	
70˚C	to	denature.	
Novex	NuPage	4-12%	bis-tris	gels	were	used	for	running	the	samples	in	MOPS	running	

















Immobilon	 FL	 membrane	 (Merck	 Millipore)	 was	 used	 for	 protein	 transfer;	 2	 pieces	
were	cut	 to	8x10cm	(cut	one	corner	at	angle	 to	allow	orientation	 later)	being	sure	 to	
touch	the	membrane	with	only	tweezers.	2	pieces	of	absorbent	paper	were	cut	to	same	
size	and	these	along	with	2	sponges	were	placed	in	transfer	buffer	(800ml	dH2O,	100ml	










it	 in	 the	 tank	 (which	 itself	 is	 sitting	 in	 a	 glass	 tray),	 black	 to	 black.	 An	 ice	 block	was	


















the	 cassette	 using	 tweezers	 and	 placed	 in	 the	 box	 (orientated	 so	 cut	 corner	 and	
standard	 ladder	are	on	 left-hand	 side)	 and	 left	 on	a	 rocker	 to	 agitate	 for	one	hour	at	
room	 temperature.	 The	 following	primary	 antibodies5	were	 applied	 in	 10ml	 5%	milk	
solution:	 MDR1/ABCB1	 (P-gp)	 Rabbit	 monoclonal	 antibody	 (D3H1Q	 Cell	 signalling	
technology®)	 at	 a	 concentration	 of	 1:1000	 (10uL)	 and	 anti-alpha	 Tubulin	 mouse	
monoclonal	antibody	(AbCam®,	ab80779)	(this	was	used	as	an	endogenous	control)	at	
a	concentration	of	1:5000	(2uL).	The	membrane	was	then	incubated	at	4˚C	overnight,	
in	 a	 small	 plastic	 pouch	 with	 the	 primary	 antibodies,	 whilst	 being	 continuously	
agitated.		The	membrane	was	then	washed	in	TBST	for	5	minutes	followed	by	TBS	three	
times	for	5	minutes	each.	Fluorescent	LiCor	secondary	antibodies	were	applied	in	10ml	
5%	milk	 solution	 both	 at	 a	 concentration	 of	 1:10000:	 1uL	Donkey	 anti	 rabbit	 (P-gp)	
and	1uL	Donkey	anti	mouse	(α-Tubulin).	This	was	then	covered	with	foil	(to	minimise	
light	exposure)	and	agitated	at	room	temperature	for	one	hour.	Washing	was	repeated	
as	above	prior	 to	being	processed	 in	a	LiCor	Odyssey®	FC	 imaging	 system,	adjusting	
the	light	intensity	for	each	channel	accordingly.	
Protein	Quantification	
Analysis	 was	 performed	 using	 Image	 Studio	 Lite	 version	 4.0	 with	 protein	 quantity	





































Maternal	age		 33	±	6.4	 31.7	±	6.1	 0.34	
Parity	 1.5	±	1.4	 0.9	±	0.7	 0.06	
BMI	 41.4	±	8.3	 41.0	±	8.1	 0.86	









































































When	 comparing	 mRNA	 levels	 of	 ABC	 B1,	 ABC	 G2	 and	 ABC	 C3	 between	 placental	

























the	ABC	B1	mRNA	levels	(see	 figure	9)	were	significantly	 lower	 in	 the	metformin	and	
insulin	 group	 compared	 to	 the	placental	 samples	 from	metformin	alone	 treated	GDM	
patients	(0.40	±	0.25	vs.	0.73	±	0.41,	p=0.026)	and	compared	to	the	samples	from	non-













10	 shows	 the	 results	 of	 the	 comparison	 of	 protein	 level	 between	 the	 GDM	 on	



















































This	 was	 compared	 to	 both	 the	 cohort	 treated	 with	 metformin	 alone	 and	 the	 non-
diabetic	cohort.	This	 finding	 is	opposite	 to	 the	hypothesis	made	prior	 to	commencing	
the	work	as	well	as	the	findings	from	the	Anger	et	al	study;	although	the	results	were	
consistent	between	the	two	studies	 in	that	 the	difference	 in	ABC	B1	mRNA	levels	was	
not	 translated	to	any	changes	 in	protein	 level.	Earlier	work	by	Anger	et	al	using	a	rat	
model	 demonstrated	 a	 significant	 elevation	 in	ABC	B1	 in	 the	 placenta	 from	 rats	with	
streptozotocin-induced	GDM	[109].	 Interestingly,	 a	 cohort	of	 the	 rats	with	GDM	were	
also	treated	with	insulin	to	treat	hyperglycaemia	and	among	this	cohort,	the	elevation	
in	ABC	B1	seen	in	the	treated	GDM	cohort	normalised	back	to	levels	approximating	to	
those	 in	 the	non-diabetic	cohort.	Whilst	 these	 findings	did	not	 translate	across	 to	 the	







decrease	 in	expression	of	ABC	B1,	 similar	to	that	seen	 in	the	cohort	of	placentas	 from	
women	with	GDM	treated	with	metformin	+	insulin	from	our	work.	
Another	reason	for	the	discrepancy	between	the	Anger	et	al	study	and	our	result	may	
be	 as	 a	 result	 of	 Anger	 failing	 to	 control	 for	 BMI	 between	 the	 GDM	 and	 non-GDM	
placental	 samples,	 this	was	 controlled	 for	 in	 our	 samples	 (as	 can	 be	 seen	 in	 figure	 7	
above)	 with	 no	 significant	 difference	 between	 any	 of	 the	 treatment	 groups.	 When	
analysing	 the	 mRNA	 levels	 according	 to	 BMI	 there	 was	 no	 significant	 trend	 in	
expression	of	any	of	the	genes	of	interest	according	to	BMI.	
The	 main	 difference	 between	 the	 cohorts	 of	 placental	 samples	 used	 in	 our	 study	
compared	 to	 those	 from	the	Anger	study	was	 the	variance	 in	 treatment	 for	GDM	that	
the	 women	 had	 been	 on	 during	 their	 pregnancies.	 Whilst	 we	 looked	 at	 placental	
samples	from	women	on	diet	alone,	metformin	and	metformin	and	insulin,	Anger	only	
looked	 at	 samples	 from	 women	 treated	 with	 insulin	 alone.	 However,	 based	 upon	
Anger’s	 findings,	 the	 hypothesis	 was	 that	ABC	B1	 levels	 would	 increase	 in	 placentas	
from	women	treated	with	insulin.	If	we	were	to	extrapolate	this,	I	would	have	expected	
to	 see	 this	 even	 in	 the	 cohort	 on	metformin	 and	 insulin	 compared	 to	 those	 only	 on	
metformin	however	the	opposite	finding	was	seen.	
Despite	 the	differences	 between	our	work	 and	 that	 of	Anger	 et	 al,	we	have	provided	
novel	 work	 looking	 at	 the	 impact	 of	 GDM	 treated	 with	 OHAs	 on	 the	 levels	 of	 ABC	
transporters	in	the	placenta.	This	study	benefited	from	a	large	sample	size	and	also	the	
samples	 were	 collected	 after	 the	 completion	 of	 treatment	 (retrospective	 design);	
thereby	ensuring	that	the	treatment	taken	by	the	patients	reflects	those	of	patients	in	

















seem	 to	 be	 a	 reduction	 of	 ABC	B1	 mRNA	 level	 among	 those	 samples	 obtained	 from	
women	with	GDM	treated	with	metformin	and	insulin	compared	to	those	treated	with	
metformin	alone	and	those	who	were	not	diabetic,	although	this	does	not	translate	to	a	
difference	 in	 protein	 level.	 These	 findings	 are	 reassuring	 in	 support	 of	 the	 use	 of	
metformin	for	the	treatment	of	GDM	as	it	suggests	that	the	disease	itself	will	not	render	












from	women	with	GDM.	However,	 glibenclamide	 is	not	a	 treatment	 currently	used	 in	
NHS	Lothian	therefore	there	were	no	samples	in	the	ERTBB	to	conduct	this	work	on.	It	
is	also	likely	that	over	coming	years	the	combination	of	two	OHAs	(such	as	metformin	
and	glibenclamide)	will	be	used	 to	 treat	GDM;	 this	 is	a	well-recognised	 treatment	 for	
type	 2	 diabetes	 mellitus	 outwith	 pregnancy,	 known	 to	 delay	 or	 even	 avoid	 insulin	
therapy	in	a	large	proportion	of	patients.	Therefore	it	would	seem	pertinent	to	examine	




- Placental	 explant	 culture	 in	 metformin	 and	 glibenclamide	 to	 assess	 whether	
exposure	 to	 these	 drugs	 alters	 the	mRNA	 expression	 of	 the	 above	mentioned	
ABC	and	GLUT	1	transporters.		
GLUT	1	 is	 the	primary	 transporter	 responsible	 for	 the	 transfer	of	 glucose	 to	 the	 fetal	
circulation,	with	a	higher	presence	on	the	microvillus	membrane	compared	to	the	basal	
membrane	 [110].	 It	 has	 been	 hypothesised	 that	 this	 asymmetric	 distribution	 means	
that	 the	 transporters	 on	 the	 basal	membrane	 act	 as	 the	 rate	 limiting	 step	 in	 glucose	















Whilst	 it	 could	 be	 argued	 that	 the	 ABC	 transporters	 are	 preventing	 the	 drugs	 from	
accumulating	in	the	placental	circulation	so	thereby	making	any	action	of	the	drugs	on	
the	 transporters	 unlikely;	 it	 is	 well	 known	 that	 these	 transporters	 are	 not	 100%	
effective	with	evidence	showing	that	whilst	most	of	the	medications	get	effluxed	away	





























between	 20	 and	 30m/kg2	 undergoing	 an	 elective	 caesarean	 section	 delivery	 at	
Simpson’s	 Centre	 for	 Reproductive	 Health	 Edinburgh	 (again	 these	 samples	 were	
obtained	 under	 the	 umbrella	 of	 the	 ERTBB).	 Following	 delivery	 of	 the	 placenta,	 an	
8x10cm	 full-thickness	 specimen	 was	 obtained	 and	 placed	 in	 DPBS	 at	 room	
temperature.	 It	 was	 then	 immediately	 transferred	 to	 the	 laboratory	 where	 the	
specimen	 was	 inspected,	 washed	 in	 DPBS	 to	 remove	 excess	 blood	 and	 explants	
measuring	70-100mg	were	obtained	from	the	maternal-facing	surface	of	the	placenta,	
attempting	 to	 avoid	 blood	 vessels/granulation	 tissue	 (4	 samples	 representative	 of	
those	cut	were	weighed	to	check	the	weight).	
The	 following	 culture	 mediums	 were	 made	 with	 these	 drug	 concentrations	 chosen	

















24	 well	 Corning®	 Costar®	 cell	 culture	 plates	 were	 then	 set	 up	 to	 contain	 the	
appropriate	 concentration	 of	 each	 drug	 and	 CCM	 in	 the	 respective	 wells	 with	 each	
condition	 repeated	 4	 times	 and	 then	 the	 placental	 sample	 added	 to	 each	 well.	 The	
culture	plates	were	then	incubated	in	37˚C,	5%	Co2	for	24hrs.	
Cultures	were	performed	eight	times	(eight	different	placentas),	with	four	repeats	 for	
each	 placenta	 in	 each	 culture	 condition,	 giving	 an	 n	 of	 32.	 For	 2	 of	 the	 placental	
samples,	 additional	 explants	 were	 run	 in	 the	 above	 conditions	 but	 these	 ones	 were	
removed	after	2	hours.	
Following	the	culture	period,	50-100uL	supernatant	was	removed	and	placed	in	0.2ml	
Eppendorf	 tubes	 and	 placed	 in	 -20°C	 freezer.	 Placental	 samples	 were	 then	 removed	
from	the	supernatant,	blotted	to	remove	excess	fluid	and	snap	frozen	on	dry	ice	prior	to	
storage	 at	 -80˚C.	 RT	 qPCR	 was	 later	 performed	 on	 these	 samples,	 analysing	 the	
expression	of	ABC	B1,	ABC	G2,	ABC	C3	and	GLUT	transporters	(same	method	used	as	in	
chapter	3).		














(all	 samples	 were	 run	 in	 triplicate).	 The	 relative	 expression	 values	 were	 calculated	
normalising	 for	 the	endogenous	 control	 (YWHAZ)	 and	 for	 an	 internal	 control	 sample.	
GraphPad®	Prism	6	was	used	to	perform	statistical	analysis	and	draw	figures.		Normal	
distribution	was	 tested	 using	 a	 Shapiro-Wilk	 normality	 test	 and	 differences	 between	
groups	 were	 tested	 initially	 using	 an	 ANOVA	 analysis	 (if	 normally	 distributed)	 or	
Kruskal-Wallis	test	(for	non-normally	distributed	results)	and	then	individual	unpaired	
t-tests	for	continuous	variables	and	chi-squared	test	for	categorical	variables	between	
the	 groups.	 Data	 are	 presented	 as	 mean	 and	 standard	 deviation	 unless	 stipulated	
otherwise.	
4.3	RESULTS	
































































24hour	 culture,	 i.e.	 there	was	 no	 significant	 difference	 in	mRNA	 level	 for	 any	 of	 the	
genes	of	interest	between	the	different	culture	conditions.	
Samples	 of	 the	 supernatant	were	 collected	 and	 analysed	 for	 lactate	 level	 at	 2hrs	 and	
24hrs	of	culture	as	a	measure	of	 tissue	viability.	Figure	13	demonstrates	a	significant	











expression	 of	 the	 ABC	 transporters	 in	 the	 placenta	 and	 looked	 at	 the	 impact	 of	
treatment	with	metformin	and	metformin	+	insulin.	We	then	extended	the	work	to	look	













was	 repeated	 four	 times	 for	 each	 placenta	 (giving	 an	n	 of	 32).	 Examining	 the	mRNA	
levels	 of	 the	 ABC	 and	 GLUT	 1	 transporters	 after	 24	 hours	 of	 culture	 failed	 to	
demonstrate	any	change	in	levels	among	any	of	the	culture	conditions.	
Eight	of	the	cultures	ran	for	24	hours	under	the	conditions	described	above.	For	two	of	
the	cultures,	extra	samples	were	run	and	 these	were	removed	after	 two	hours	 to	see	




for	 some	 of	 the	 different	 transporters	 seen	 between	 the	 two	 hours	 and	 24	 hours	 of	
culture.		
24	hours	culture	time	was	initially	chosen	as	it	was	felt	that	this	would	be	long	enough	
to	 allow	 any	mRNA	modification	 to	 occur	 if	 it	 was	 going	 to	 happen	 and	 also	 still	 be	
within	 the	 time	 of	 tissue	 viability	 demonstrated	 in	 several	 papers,	 although	 it	 was	
noted	 that	 there	 was	 a	 degree	 of	 tissue	 degeneration	 during	 the	 initial	 24	 hours	 of	
culture	[114,	115].		
Samples	of	supernatant	were	obtained	at	two	hours	and	24	hours	of	culture	from	each	
of	 the	 culture	 conditions	 and	 lactate	 levels	 were	 assessed	 as	 a	 measure	 of	 tissue	









in	 metformin,	 glibenclamide	 and	 a	 combination	 of	 both	 at	 concentrations	




the	 cultures	 had	 samples	 removed	 at	 2	 hours	 it	 is	 difficult	 to	 clearly	 assess	 the	
relevance	 of	 these	 findings.	 The	 lactate	 levels	 seen	 suggest	 that	 some	 tissue	






Figure	 14:	 accumulation	 of	 hPL	 and	 hCG	 during	 seven	 to	 24hours	 of	 placental	 culture.	
Values	given	as	mean	±	SD.	[116].	
The	 culture	medium	 used	was	made	 from	 RPMI	 that	 has	 a	 glucose	 concentration	 of	
11mmol/L.	 This	 is	 significantly	 hyperglycaemic	 and	 could	 well	 have	 resulted	 in	 an	
alteration	in	the	mRNA	levels	of	the	transporters	that	could	have	masked	any	changes	







induce	 apoptosis	 of	 culture	 tissue,	 however	 this	 was	 shown	 not	 to	 be	 the	 case	 in	 a	
paper	examining	tissue	viability	over	24	hours	[116].	It	would	have	been	ideal	to	repeat	
these	 tissue	 cultures	 under	 normoglycaemic	 conditions	 to	 explore	 any	 effect	 of	 the	
hyperglycaemia,	which	 has	 previously	 been	 shown	 to	 alter	 the	 expression	 of	GLUT	1	
and	also	ABC	G2,	however	this	was	not	possible	due	to	time	limitations.	
Another	 aspect	 that	 could	 be	 considered	 in	 further	 work	 is	 the	 gestation	 of	 the	











with	GDM	who	were	 treated	with	 these	drugs	(both	 individually	and	 in	combination)	
















diagnostic	 criteria.	 This	 increased	 incidence	 and	 knowledge	 of	 the	 importance	 of	
treating	 GDM	 to	 minimise	 the	 consequences	 of	 uncontrolled	 hyperglycaemia	 have	
driven	 the	 search	 for	 appropriate	 treatments	 forwards.	 Over	 the	 last	 8	 years	 it	 has	
become	 increasingly	 common	 to	 treat	 GDM	 with	 OHA’s	 such	 as	 metformin	 and	
glibenclamide	and	whilst	 there	 is	 a	 large	body	of	 evidence	demonstrating	 the	 clinical	
safety	and	efficacy	of	such	treatments,	little	attention	has	been	given	to	the	mechanisms	
in	place	to	protect	the	fetus	from	exposure	to	such	mediations	and	other	xenobiotics.	
Growing	evidence	has	 identified	 the	presence	of	 the	ABC	 transporters	 in	 the	placenta	
and	documented	the	role	 they	play	 in	protecting	the	 fetus	 from	unwanted	substances	
including	xenobiotics.	As	outlined	 in	 the	 literature	 review	above,	 there	are	 three	ABC	
transporters	of	particular	importance	with	regard	to	the	treatment	of	GDM	with	OHAs:	
ABC	B1,	ABC	G2	and	ABC	C3.		
The	work	 in	 this	 thesis	has	provided	 important	evidence	that	GDM	does	not	alter	 the	
very	 transporters	 that	 protect	 the	 fetus	 from	 unwanted	 exposure	 to	 the	 OHA	
treatments	 given	 to	 mothers	 for	 GDM.	 The	 culture	 work	 performed	 has	 also	
demonstrated	 that	 in	 the	 in	vitro	 setting,	 there	does	not	appear	 to	be	an	alteration	 in	
the	expression	of	ABC	B1,	ABC	G2,	ABC	C3	and	GLUT	1	 following	exposure	of	placental	
explants	 to	 metformin,	 glibenclamide	 or	 both	 at	 levels	 representative	 of	 those	 seen	
clinically	in	patients	on	the	treatment.	
The	next	steps	 following	 this	work	should	be	 to	conduct	a	clinical	 trial	 looking	at	 the	








this	would	also	provide	a	 cohort	of	placental	 samples	 from	women	who	 received	 the	
combined	treatment	during	pregnancy	allowing	a	more	realistic	examination	of	mRNA	
and	protein	levels	of	the	ABC	transporters.		




Another	 factor	 that	 has	 not	 been	 addressed	 in	 this	 work	 is	 the	 presence	 of	 BCRP	
variants,	 especially	 C421A,	which	 can	 reduce	 BCRP	 expression	 due	 to	 a	 reduction	 in	
transcriptional	efficacy.	The	C421A	variant	is	particularly	prevalent	among	Caucasians,	
Chinese	 and	 Japanese	 populations	 (10-30%)	 [69].	 Given	 that	 glibenclamide	 is	
predominately	 effluxed	 from	 the	 fetal	 circulation	 via	BCRP	 it	would	 seem	 sensible	 to	
assess	whether	transport	of	glibenclamide	is	different	between	placentas	from	women	
with	and	without	the	C421A	variant	of	BCRP.	
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